Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ipilimumab in Gliosarcoma: NCT07134842 Clinical Landscape Report 2026
28 September 2026
NCT07134842 clinical landscape for Gliosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Envafolimab in Osteosarcoma: NCT07142863 Clinical Landscape Report 2026
28 September 2026
NCT07142863 clinical landscape for Osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Domvanalimab in PD-L1 positive Triple Negative Breast Cancer: NCT07134556 Clinical Landscape Report 2026
28 September 2026
NCT07134556 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
Anlotinib Dihydrochloride in Rhabdomyosarcoma: NCT07137884 Clinical Landscape Report 2026
28 September 2026
NCT07137884 clinical landscape for Rhabdomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pidnarulex in HER2 Positive Solid Tumors: NCT07137416 Clinical Landscape Report 2026
28 September 2026
NCT07137416 clinical landscape for HER2 Positive Solid Tumors: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tegatrabetan in Osteosarcoma, Recurrent: NCT07144254 Clinical Landscape Report 2026
28 September 2026
NCT07144254 clinical landscape for Osteosarcoma, Recurrent: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anlotinib Dihydrochloride in Metastatic Triple-Negative Breast Carcinoma: NCT07139470 Clinical Landscape Report 2026
28 September 2026
NCT07139470 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Capecitabine in Triple Negative Breast Cancer: NCT07143097 Clinical Landscape Report 2026
28 September 2026
NCT07143097 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MBRC-201 in Pancreatic Ductal Adenocarcinoma: NCT07145255 Clinical Landscape Report 2026
28 September 2026
NCT07145255 clinical landscape for Pancreatic Ductal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
SC-CAR.GPC3xIL15.21 CAR T cells(Seattle Children's Hospital) in Hepatocellular Carcinoma: NCT07148050 Clinical Landscape Report 2026
28 September 2026
NCT07148050 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[Ac 225]-RTX-2358 in Refractory Soft Tissue Sarcoma: NCT07156565 Clinical Landscape Report 2026
28 September 2026
NCT07156565 clinical landscape for Refractory Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sacituzumab tirumotecan in PD-L1 positive Triple Negative Breast Cancer: NCT07153965 Clinical Landscape Report 2026
28 September 2026
NCT07153965 clinical landscape for PD-L1 positive Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and developmen…